Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine ; volume:31 ; number:6 ; day:14 ; month:8 ; year:2024 ; pages:1037-1045 ; date:11.2024
Breast cancer ; 31, Heft 6 (14.8.2024), 1037-1045, 11.2024
- Creator
-
Kitadai, Rui
Shimoi, Tatsunori
Yazaki, Shu
Okuma, Hitomi Sumiyoshi
Hoshino, Mai
Ito, Munehiro
Saito, Ayumi
Kita, Shosuke
Kojima, Yuki
Nishikawa, Tadaaki
Sudo, Kazuki
Noguchi, Emi
Fujiwara, Yasuhiro
Yoshida, Masayuki
Yonemori, Kan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-024-01617-y
- URN
-
urn:nbn:de:101:1-2501072122185.108373085512
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kitadai, Rui
- Shimoi, Tatsunori
- Yazaki, Shu
- Okuma, Hitomi Sumiyoshi
- Hoshino, Mai
- Ito, Munehiro
- Saito, Ayumi
- Kita, Shosuke
- Kojima, Yuki
- Nishikawa, Tadaaki
- Sudo, Kazuki
- Noguchi, Emi
- Fujiwara, Yasuhiro
- Yoshida, Masayuki
- Yonemori, Kan
- SpringerLink (Online service)
Other Objects (12)
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study